Progress and contrasts of the development of tivozanib for therapy of kidney cancer. - Wikidata - awgldk - TriplyDB

Progress and contrasts of the development of tivozanib for therapy of kidney cancer.

Progress and contrasts of the development of tivozanib for therapy of kidney cancer.

http://www.wikidata.org/entity/Q37958038

about

Third generation tyrosine kinase inhibitors and their development in advanced renal cell carcinoma.Targeted therapy of kidney cancer: keeping the art around the algorithms.Milestones for development of tivozanib for kidney cancer therapy.

P2860

Q38015387-BB9CF47E-FE7E-46A6-9740-2491B8164842 Q38118060-8AAF81CA-B75B-4B3B-93A1-E429B62C9C69 Q43095763-C2A52CE3-124C-42C5-8FC4-382A7DF23968

P2860

Progress and contrasts of the development of tivozanib for therapy of kidney cancer.

http://www.wikidata.org/entity/Q37958038

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Progress and contrasts of the development of tivozanib for therapy of kidney cancer.

@en

Progress and contrasts of the development of tivozanib for therapy of kidney cancer.

@nl

type

label

Progress and contrasts of the development of tivozanib for therapy of kidney cancer.

@en

Progress and contrasts of the development of tivozanib for therapy of kidney cancer.

@nl

prefLabel

Progress and contrasts of the development of tivozanib for therapy of kidney cancer.

@en

Progress and contrasts of the development of tivozanib for therapy of kidney cancer.

@nl

P1433

Q37958038-1610294F-A997-4384-824F-AE063D95F588

P1476

Q37958038-74C09843-A63A-4E7E-8A12-3D8EB88FC8DE

P2093

Q37958038-B3D1B173-71AA-473E-BF59-7695B1698A01

Q37958038-E9E89043-930F-43E0-866B-91F0ED55E76F

P2860

Q37958038-05E85979-E2FF-41E5-BB66-0610E74B49C7

Q37958038-095D5A95-1D71-48D2-A3F3-8F4F33125774

Q37958038-17C557F2-D249-43CD-AA1F-397F555F9078

Q37958038-1ACDCB15-9591-40D2-A69D-15EB3C76EC87

Q37958038-1BA88948-E977-4E03-BD69-2043B544DEE5

Q37958038-1BB441DD-8B42-4498-9F1B-9000222E567B

Q37958038-1C5A8366-302B-44A7-9B2D-91C74AFF5A9F

Q37958038-2CF08507-213A-4065-9D80-59C7BDE7CFCB

Q37958038-39AD740A-6661-40ED-8FF0-B423CB434960

Q37958038-4A1A0F06-652B-4829-A38D-92645B409767

P304

Q37958038-02AB1FB4-3B45-432C-AEB2-F93F68FEA2A5

P31

Q37958038-CCAAFDB3-309D-40CF-BFD2-BFC50DF31C62

P356

Q37958038-7E51415E-C96E-4251-A940-0C0028BB3E46

P407

Q37958038-3967499F-5D01-45DD-BA47-773399B8D948

P433

Q37958038-7C74353B-0FCA-4F3D-BEC6-825B68225A45

P478

Q37958038-C8D211E9-ED7F-42DE-B006-8C6593DE5BA7

P577

Q37958038-E9B817FB-4AC1-48BA-B2C4-A0061F597BDA

P698

Q37958038-1B8FBE13-D900-4B2E-8967-F4DD6A37BE0C

P356

14656566.2011.636032

P1433

Expert Opinion on Pharmacotherapy

P1476

Progress and contrasts of the development of tivozanib for therapy of kidney cancer.

@en

P2093

Mayer Fishman

http://www.w3.org/2001/XMLSchema#string

Shilpa Gupta

http://www.w3.org/2001/XMLSchema#string

P2860

Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker

c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion

Structure and function of VEGF/VEGF-receptor system involved in angiogenesis.

Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study.

Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors.

Development of second-generation VEGFR tyrosine kinase inhibitors: current status.

P304

2915-2922

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656566.2011.636032

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2011-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22098229

http://www.w3.org/2001/XMLSchema#string